Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H16N3O4S.Na |
Molecular Weight | 333.339 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CN(CS([O-])(=O)=O)C1=C(C)N(C)N(C1=O)C2=CC=CC=C2
InChI
InChIKey=DJGAAPFSPWAYTJ-UHFFFAOYSA-M
InChI=1S/C13H17N3O4S.Na/c1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11;/h4-8H,9H2,1-3H3,(H,18,19,20);/q;+1/p-1
DescriptionSources: http://www.un.org/esa/coordination/CL12.pdf
Sources: http://www.un.org/esa/coordination/CL12.pdf
Dipyrone, also known as Metamizole (INN), is an ampyrone sulfonate analgesic, antispasmodic and antipyretic. It was withdrawn from US market in 1977 on the basis of reports of agranulocytosis. Depyrone is still used to treat severe and diffucult for relieving pains of different origin; headache, tooth-ache, pains in the joints, muscles, following traumas and operations, gall and kidney colics, neurites, neuralgias, traumatic cerebrasthenia; inflammation of upper respiratory ways of microbial or virus origin; chorea; febrile states. Mechanism of action of dipyrone is complex. It is believed that dipyrone exerts its action by inhibiting COX-3, and activates opioid and cannabioid systems either itself, or by products of its metabolic degradation.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P23219|||Q5T7T7 Gene ID: 5742.0 Gene Symbol: PTGS1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12242329 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NEURALGIN Approved UseSevere and diffucult for relieving pains of different origin; headache, tooth-ache, pains in the joints, muscles, following traumas and operations, gall and kidney colics, neurites, neuralgias, traumatic cerebrasthenia; inflammation of upper respiratory ways of microbial or virus origin; chorea; febrile states. |
|||
Primary | OPTALGIN Approved UseOptalgin Injection, by intramuscular administration, is indicated to lower temperature in life-threatening situations, when this cannot be achieved by other means. Hyperthermic patients in critical condition may also be treated in non-hospital environment, under close medical supervision. |
PubMed
Title | Date | PubMed |
---|---|---|
Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. | 1984 |
|
Diagnosis of antibody-mediated drug allergy. Pyrazolinone and pyrazolidinedione cross-reactivity relationships. | 1987 Nov |
|
Modifying effects of a mixture of acetaminophen, aspirin, dipyrone and ethenzamide on a multiorgan initiation model and its carcinogenicity in male F344 rats. | 1999 Jan 8 |
|
COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. | 2002 Oct 15 |
|
Effects of celecoxib on acid-challenged gastric mucosa of rats: comparison with metamizol and piroxicam. | 2004 Jun |
|
[Acute intermittent porphyria and oral contraception. Case report]. | 2006 Mar |
|
Lack of effect of naltrindole on the spinal synergism of morphine and non-steroidal anti-inflammatory drugs (NSAIDS). | 2009 Jun |
|
Over-expression of the LTC4 synthase gene in mice reproduces human aspirin-induced asthma. | 2011 Aug |
Sample Use Guides
Dipyrone was administered orally, as subcutaneous and intramuscular injections (daily dose 0.25-1 g as 50% solution), or by intravenous injection.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12242329
Cyclooxygenase activity was measured by the formation of PGE2 after exposure to exogenous 30 μM acid for 10 min. Dipyrone inhibited COX-1 with IC50 350 uM, and COX-3 with IC50 of 52 uM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
N02BB52
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
||
|
WHO-VATC |
QN02BB02
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
||
|
WHO-VATC |
QN02BB72
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
||
|
WHO-ATC |
N02BB72
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
||
|
WHO-ATC |
N02BB02
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
||
|
WHO-VATC |
QN02BB52
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C170166
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY | |||
|
522325
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY | |||
|
200-694-7
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY | |||
|
VSU62Z74ON
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY | |||
|
CHEMBL461522
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY | |||
|
VSU62Z74ON
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY | |||
|
1537943
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB08810MIG
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY | |||
|
59033
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY | |||
|
DBSALT000332
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY | |||
|
100000091714
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY | |||
|
DTXSID8020543
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY | |||
|
68-89-3
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY | |||
|
477
Created by
admin on Fri Dec 15 16:53:21 GMT 2023 , Edited by admin on Fri Dec 15 16:53:21 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD